[HTML][HTML] Niclosamide revitalizes sorafenib through insulin-like growth factor 1 receptor (IGF-1R)/stemness and metabolic changes in hepatocellular carcinoma
SW Peng, MHT Ngo, YC Kuo, MH Teng, CL Guo… - Cancers, 2023 - mdpi.com
Simple Summary Sorafenib resistance is the major challenge for the unsatisfactory response
to targeted therapies in advanced hepatocellular carcinoma (HCC). Combination therapy …
to targeted therapies in advanced hepatocellular carcinoma (HCC). Combination therapy …
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
SW Peng, MHT Ngo, YC Kuo, MH Teng, G Chin-Lin… - …, 2023 - search.proquest.com
Sorafenib is the first approved systemic targeting agent for advanced HCC; however, when
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
S Peng, M Ngo, Y Kuo, M Teng, C Guo, H Lai, T Chang… - Cancers, 2023 - europepmc.org
Sorafenib is the first approved systemic targeting agent for advanced HCC; however, when
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
SW Peng, MHT Ngo, YC Kuo, MH Teng, CL Guo… - …, 2023 - pubmed.ncbi.nlm.nih.gov
Sorafenib is the first approved systemic targeting agent for advanced HCC; however, when
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
SW Peng, MHT Ngo, YC Kuo, MH Teng, CL Guo… - …, 2023 - pure.lib.cgu.edu.tw
Sorafenib is the first approved systemic targeting agent for advanced HCC; however, when
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
[引用][C] Niclosamide Revitalizes Sorafenib through Insulin-Like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
SW Peng, MHT Ngo, YC Kuo, MH Teng, CL Guo… - Cancers 15 (3) …, 2023 - ir.sinica.edu.tw
Issue Date: 2023-02-01 Relation: Cancers 15 (3), 931 URI: http://ir. sinica. edu. tw/handle/
201000000A/87765 ISSN: http://gateway. isiknowledge. com/gateway/Gateway. cgi …
201000000A/87765 ISSN: http://gateway. isiknowledge. com/gateway/Gateway. cgi …
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma.
SW Peng, MHT Ngo, YC Kuo, MH Teng, CL Guo… - …, 2023 - search.ebscohost.com
Abstract Simple Summary: Sorafenib resistance is the major challenge for the unsatisfactory
response to targeted therapies in advanced hepatocellular carcinoma (HCC). Combination …
response to targeted therapies in advanced hepatocellular carcinoma (HCC). Combination …
[HTML][HTML] Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
SW Peng, MHT Ngo, YC Kuo, MH Teng, CL Guo… - Cancers, 2023 - ncbi.nlm.nih.gov
Sorafenib is the first approved systemic targeting agent for advanced HCC; however, when
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
SW Peng, MHT Ngo, YC Kuo, MH Teng, CL Guo… - Cancers, 2023 - hub.tmu.edu.tw
Sorafenib is the first approved systemic targeting agent for advanced HCC; however, when
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
used alone, drug resistance can result in considerably reduced efficacy. Here, we …
Niclosamide Revitalizes Sorafenib through Insulin-like Growth Factor 1 Receptor (IGF-1R)/Stemness and Metabolic Changes in Hepatocellular Carcinoma
SW Peng, MHT Ngo, YC Kuo, MH Teng, CL Guo… - Cancers, 2023 - hub.tmu.edu.tw
摘要Sorafenib is the first approved systemic targeting agent for advanced HCC; however,
when used alone, drug resistance can result in considerably reduced efficacy. Here, we …
when used alone, drug resistance can result in considerably reduced efficacy. Here, we …